Research has demonstrated that inhibiting the EGFR oncogene activates the NF-κB signaling pathway in lung cancer, subsequently increasing the expression of the apolipoprotein B mRNA-editing catalytic polypeptide-like (APOBEC) enzyme APOBEC3B (A3B) [98]. This evidence concerns the gene APOBEC3B and lung carcinoma.